Federal Grant Award Summary

Georgetown University received a $754,873 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) with an award date of July 1, 2026, and a completion date of June 30, 2029. The research initiative, titled "Targeting WNK1 to Disrupt Cell Volume Control in Triple-Negative Breast Cancer," focuses on investigating the role of the WNK1 protein in regulating cellular volume mechanisms within triple-negative breast cancer cells. This project represents a hypothesis-driven biomedical research effort designed to advance innovative therapeutic strategies for cancer treatment, aligning with the Defense Health Agency's mission to transform healthcare for service members and the American public through targeted medical research.

The award supports basic and translational research activities to be conducted at Georgetown University's Washington, D.C. campus. As a major research institution with extensive experience in Defense Health Agency-funded oncology research, Georgetown will deliver research and development services including laboratory investigations, data analysis, and scientific findings that contribute to the broader portfolio of cancer immunotherapy and precision medicine initiatives funded under the Military Medical Research and Development program. The three-year performance period allows for comprehensive investigation into cellular mechanisms that could inform future therapeutic interventions for triple-negative breast cancer, a particularly aggressive form of breast malignancy.